Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; MPH-966, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. The company also develops OMP-305B83 and OMP-313M32, which are anti-cancer therapeutic candidates in clinical development stage. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone44-0-33-3023-7300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees37
Next Earnings DateN/A
OptionableNot Optionable
Mereo BioPharma Group (NASDAQ:MREO) Frequently Asked Questions
What is Mereo BioPharma Group's stock symbol?
Mereo BioPharma Group trades on the NASDAQ under the ticker symbol "MREO."
What is the consensus analysts' recommendation for Mereo BioPharma Group?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mereo BioPharma Group in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mereo BioPharma Group.
Has Mereo BioPharma Group been receiving favorable news coverage?
Media stories about MREO stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mereo BioPharma Group earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Mereo BioPharma Group.
Who are some of Mereo BioPharma Group's key competitors?
Some companies that are related to Mereo BioPharma Group include Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Capstone Therapeutics (CAPS), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM), Myrexis (MYRX), Orexigen Therapeutics (OREX), Pivot Pharmaceuticals (PVOTF) and Pivotal Therapeutics (PVTTF).
What other stocks do shareholders of Mereo BioPharma Group own?
Who are Mereo BioPharma Group's key executives?
Mereo BioPharma Group's management team includes the folowing people:
- Dr. Denise Scots-Knight, Co-Founder, CEO & Exec. Director (Age 60)
- Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 50)
- Dr. Alastair MacKinnon, Co-Founder & Chief Medical Officer (Age 49)
- Mr. John Richard, Co-Founder & Head of Corp. Devel. (Age 62)
- Mr. Richard Crispin Morgan Jones, CFO & Exec. Director (Age 53)
When did Mereo BioPharma Group IPO?
(MREO) raised $49 million in an initial public offering (IPO) on the week of April 23rd 2018. The company issued 2,800,000 shares at $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers.
How do I buy shares of Mereo BioPharma Group?
Shares of MREO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mereo BioPharma Group's stock price today?
One share of MREO stock can currently be purchased for approximately $3.40.
What is Mereo BioPharma Group's official website?
How can I contact Mereo BioPharma Group?
Mereo BioPharma Group's mailing address is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. The company can be reached via phone at 44-0-33-3023-7300.
MarketBeat Community Rating for Mereo BioPharma Group (NASDAQ MREO)
MarketBeat's community ratings are surveys of what our community members think about Mereo BioPharma Group and other stocks. Vote "Outperform" if you believe MREO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MREO will underperform the S&P 500 over the long term. You may vote once every thirty days.
